Jasper Therapeutics

OverviewSuggest Edit

Jasper is a biotechnology company focused on enabling safer conditioning agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. The company's lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.


Latest Updates

Cybersecurity ratingFMore

Key People/Management at Jasper Therapeutics

Bill Lis

Bill Lis

Executive Chairman and Interim CEO
Mitchell Mutz

Mitchell Mutz

Jeet Mahal

Jeet Mahal

Chief Financial and Business Officer
Judith Shizuru

Judith Shizuru

Kevin Heller

Kevin Heller

Executive Vice President, Research and Development
Carol Zoltowski

Carol Zoltowski

Senior Vice President, Regulatory Affairs and Quality
Show more

Jasper Therapeutics Financials and Metrics

Summary Metrics

Jasper Therapeutics total Funding

$49.1 m

Jasper Therapeutics latest funding size

$14.10 m

Time since last funding

a year ago

Jasper Therapeutics investors

Jasper Therapeutics's latest funding round in January 2020 was reported to be $14.1 m. In total, Jasper Therapeutics has raised $49.1 m
Show all financial metrics

Jasper Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Jasper Therapeutics Online and Social Media Presence

Embed Graph

Jasper Therapeutics Frequently Asked Questions

  • Who are Jasper Therapeutics key executives?

    Jasper Therapeutics's key executives are Bill Lis, Mitchell Mutz and Jeet Mahal.

  • Who are Jasper Therapeutics competitors?

    Competitors of Jasper Therapeutics include Transgene, ProtoKinetix and Cord Blood America.